Comparison of reporting between sources in CHERISH
| Outcomes reported | Brunner et al20 | ClinicalTrials.gov | |
|---|---|---|---|
| Patients with JIA ACR30 flare (weeks 16–40) (%) | ✓ | ✓ | |
| Patients achieving JIA ACR 30/50/70/90 responses (baseline to week 16) (%) | ✓ | ✓ | |
| All JIA core response variables at week 16 | ✕ | ✓ | |
| Patients achieving JIA ACR 30/50/70/90 responses (week 40) (%) | ✓ | ✓ | |
| Change from baseline | JIA ACR component score physician global assessment of disease activity (week 40) | ✓ | ✓ |
| JIA ACR component score patient/parent global assessment of overall well-being (week 40) | ✓ | ✓ | |
| JIA ACR component score number of joints with active arthritis (week 40) | ✓ | ✓ | |
| JIA ACR component score number of joints with limitation of movement (week 40) | ✓ | ✓ | |
| JIA ACR component score ESR (week 40) | ✓ | ✓ | |
| JIA ACR component score CHAQ-DI (week 40) | ✓ | ✓ | |
| Pain VAS score (week 40) | ✓ | ✓ | |
| Patients with inactive disease (week 40) (%) | ✓ | ✓ | |
| All outcomes at week 104 | ✕ | ✓ |
ACR, American College of Rheumatology; CHAQ-D, Childhood Health Assessment Questionnaire-Disability Index; ESR, erythrocyte sedimentation rate; JIA, juvenile idiopathic arthritis; VAS, visual analogue scale.